Instrument Inactif

Autres langues Exicure Inc Other OTC

Actions

US30205M1018

Recherche biotechnologique et médicale

Autres langues

03/08	Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
30/06	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026
30/06	Exicure Announces Board and Committee Changes
10/06	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
01/06	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
29/05	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
23/04	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)
23/04	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
23/04	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)
10/04	Exicure, Inc. Announces Management Changes
02/04	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
27/03	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026
25/03	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
25/03	Exicure, Inc. Reports Full Year 2025 Financial Results
25/03	Exicure, Inc. Auditor Raises 'Going Concern' Doubt
18/02	Exicure appoints Jung Soo Kim as CEO and president
17/02	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026
17/02	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026
17/02	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026
10/02	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026
10/02	Exicure, Inc. Announces Resignation of Andy Yoo as Chief Executive Officer, Effective February 9, 2026
10/02	Exicure, Inc. Announces Management Changes, Effective February 9, 2026
05/02	Exicure, Inc. Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
05/02	Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
21/01	Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings